Effect of S-adenosyl-L-methionine in patients with primary biliary cholangitis treated with ursodeoxycholic acid

Abstract

Abstract: Objective To investigate the effect of S-Adenosyl-L-Methionine (SAMe) supplementation on liver biochemistry and liver stiffness measurement (LSM) value in patients with primary biliary cholangitis (PBC), treated with Ursodeoxycholic acid (UDCA).Methods The all 50 patients with PBC were enrolled and divided into two groups randomly and averagely. They had received UDCA treatment. The patients in observation group additionally had been treated with SAMe in the dose of 1000 mg daily over a period of 24 weeks. SAMe had been injected intravenously for two weeks and then orally treated. Liver function and LSM were measured before treatment, 6 months after treatment and 1 year after treatment.Results The therapeutic effect was judged by Ehime standard after 6 months’ treatment. There were 23 cases had response in observation group (92.0%), significantly higher than that in the control group (17 cases, 68.0%, P=0.034). The therapeutic effect was judged by Barcelona standard after 1 year treatment. There were 20 cases had response in the treatment group (80.0%), which was higher than that in the control group (17 cases, 68.0%), but the difference was not statistically significant (P=0.333). 6 months and 1 year after treatment, LSM value in observation group was [(6.6±2.5)kPa, (6.8±3.0) kPa], which was lower than that in control group [(6.8±3.0)kPa, (7.4±2.7) kPa], but the difference was not statistically significant as well. There were no serious adverse reactions in both groups.Conclusion Our study demonstrates a positive effect of adding SAMe to UDCA in patients with PBC in near future.

Key words: S-Adenosyl-L-Methionine, Primary biliary cholangitis, Effect

DU Xiao-fei, CHEN Jie, REN Shan, ZHANG Xiao-dan, HUANG Chun-yang, SHAN Jing. Effect of S-adenosyl-L-methionine in patients with primary biliary cholangitis treated with ursodeoxycholic acid[J]. Chinese Hepatolgy, 2021, 26(6): 661-663.

References

[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017,67:145-172.
[2] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015).中华传染病杂志,2016,34:385-394.
[3] Guo T, Chang L, Xiao Y, et al. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015,10:e0122124.
[4] Wunsch E, Raszeja-Wyszomirska J, Barbier O, et al. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis, 2018,27:273-279.
[5] Kilanczyk E, Banales JM, Wunsch E, et al. S-adenosyl-L-methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S-glutathionylation processes in cholangiocytes. Biochim Biophys Acta Mol Basis Dis, 2020,1866:165895.
[6] Azemoto N, Abe M, Murata Y, et al. Earlybiochemicalresponse to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol, 2009,44:630-634.
[7] Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology, 2006,130:715-720.
[8] 边新渠,陈杰,刘燕敏,等.熊去氧胆酸治疗原发性胆汁性胆管炎患者血清甲状腺激素水平变化.实用肝脏病杂志,2019,22:716-719.
[9] 陈杰,黄春洋,黄云丽,等.大黄利胆胶囊对熊去氧胆酸经治的原发性胆汁性胆管炎患者临床疗效观察.中西医结合肝病杂志,2020,30:492-494.
[10] 王建军,赵平. S-腺苷蛋氨酸临床应用研究进展.2011,3:57-60.
[11] 郝娟,吕靖,邢枫,等.原发性胆汁性胆管炎的药物治疗进展.临床肝胆病杂志,2020,36:222-226.
[12] Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol, 2012,57:1097-1109.